Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma

International Journal of Hyperthermia

Volumn 22, Issue 2, 2006, Pages 161-172

  Jones, Ellen ^a   Secord, Angeles Alvarez ^a   Prosnitz, Leonard R ^a   Samulski, Thaddeus V ^a   Oleson, James R ^a   Berchuck, Andrew ^a   Clarke Pearson, Daniel ^a   Soper, John ^a   Dewhirst, Mark W ^a   Vujaskovic, Zeljko ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Hyperthermia; Intra peritoneal; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; LORAZEPAM; MELPHALAN; METOCLOPRAMIDE; PACLITAXEL; THIOSULFATE;

ADULT; ADVANCED CANCER; ANAPHYLAXIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THERMOMETRY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 33646421436     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730500515270     Document Type: Article

References (34)

1. Ozols, RF. (2000) Optimum chemotherapy for ovarian cancer International Journal of Gynecological Cancer, 10, pp. 33-37.
2. McGuire, WP and Brady, MF and Ozols, RF. (1999) The Gynecologic Oncology Group experience in overian cancer Annals of Oncology, 10(Suppl 1), pp. 29-34.
3. Piccart, MJ and Lamb, H and Vermorken, JB. (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer Annals of Oncology, 12, pp. 1195-1203.
4. Levin, L and Hryniuk, WM. (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma Journal of Clinical Oncology, 5, pp. 756-767.
5. MacGibbon, A and Bucci, J and MacLeod, C and Solomon, J and Dalrymple, C and Firth, I and Carter, J. (1999) Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma Gynecology & Oncology, 75, pp. 62-67.
6. Firat, S and Murray, K and Erickson, B. (2003) High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: Long-term toxicity and outcomes International Journal of Radiation Oncology, Biology & Physics, 57, pp. 201-207.
7. Sedlacek, TV and Spyropoulus, P and Cifaldi, R and Glassburn, J and Fisher, S. (1997) Whole-abdomen radiation therapy as salvage treatment for epithelial ovarian carcinoma Cancer Journal of Science America, 3, pp. 358-363.
8. Runowicz, CD. (1993) To P32 or not to P32, that is the question Gynecology & Oncology, 50, pp. 139-140.
9. Alberts, DS and Liu, PY and Hannigan, EV and O'Toole, R and Williams, SD and Young, JA and Franklin, EW and Clarke-Pearson, DL and Malviya, VK and DuBeshter, B. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer New England Journal of Medicine, 335, pp. 1950-1955.
10. Recio, FO and Piver, MS and Hempling, RE and Driscoll, DL. (1998) Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer Gynecology & Oncology, 68, pp. 267-273.
11. Dedrick, RL and Myers, CE and Bungay, PM and DeVita, VT, Jr. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treatment Reports, 62, pp. 1-11.
12. Piver, MS and Lele, SB and Marchetti, DL and Baker, TR and Emrich, LJ and Hartman, AB. (1988) Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma Journal of Clinical Oncology, 6, pp. 1679-1684.
13. Cannon, MJ and Santin, AD and O'Brien, TJ. (2004) Immunological treatment of ovarian cancer Current Opinions in Obstetrics & Gynecology, 16, pp. 87-92.
14. Berek, JS and Schultes, BC and Nicodemus, CF. (2003) Biologic and immunologic therapies for ovarian cancer Journal of Clinical Oncology, 21(10 Suppl), pp. 168-174.
15. Leopold, KA and Oleson, JR and Clarke-Pearson, D and Soper, J and Berchuck, A and Samulski, TV and Page, RL and Blivin, J and Tomberlin, JK and Dewhirst, MW. (1993) Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma International Journal of Radiation Oncology, Biology & Physics, 27, pp. 1245-1251.
16. Westermann, AM and Grosen, EA and Katschinski, DM and Jager, D and Rietbroek, R and Schink, JC and Tiggelaar, CL and Jager, E and Zum Vorde sive Vording, P and Neuman, A and Knuth, A and Van Dijk, JD and Wiedemann, GJ and Robins, HI. (2001) A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer European Journal of Cancer, 37, pp. 1111-1117.
17. Van de Vaart, PJ and van der Vange, N and Zoetmulder, FA and van Goethem, AR and van Tellingen, O and Ten Bokkel Huinink, WW and Beijnen, JH and Bartelink, H and Begg, AC. (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines European Journal of Cancer, 34, pp. 148-154.
18. Formenti, SC and Shrivastava, PN and Sapozink, M and Jozsef, G and Chan, KK and Jeffers, S and Morrow, PC and Muggia, FM. (1996) Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: Feasibility, tolerance and pharmacology International Journal of Radiation Oncology, Biology & Physics, 35, pp. 993-1001.
19. Markman, M and Reichman, B and Hakes, T and Curtin, J and Jones, W and Lewis, JL and Barakat, R and Rubin, S and Mychalczak, B and Saigo, P and Almadrones, L and Hoskins, W. (1993) Intraperitoneal chemotherapy in the management of ovarian cancer Cancer, 71(4 Suppl), pp. 1565-1570.
20. Markman, M and Bundy, BN and Alberts, DS and Fowler, JM and Clark-Pearson, DL and Carson, LF and Wadler, S and Sickel, J. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group Journal of Clinical Oncology, 19, pp. 1001-1007.
21. Spratt, JS and Adcock, RA and Sherrill, W and Travathen, S. (1980) Hyperthermic peritoneal perfusion system in canines Cancer Research, 40, pp. 253-255.
22. Smith, GV and MacMillan, R and Stribling, J. (1983) Intraperitoneal approach to regional hyperthermia - possible anticancer applications World Journal of Surgery, 7, pp. 732-737.
23. Herman, TS. (1983) Temperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro Cancer Research, 43, pp. 517-520.
24. Stewart, DJ and Benjamin, RS and Luna, M and Feun, L and Caprioli, R and Seifert, W and Loo, TL. (1982) Human tissue distribution of platinum after cis-diamminedichloroplatinum Cancer Chemotherapy & Pharmacology, 10, pp. 51-54.
25. Herman, TS and Teicher, BA and Chan, V and Collins, LS and Abrams, MJ. (1989) Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes International Journal of Radiation Oncology, Biology & Physics, 16, pp. 443-449.
26. Wallner, KE and Li, GC. (1987) Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin Cancer Research, 47, pp. 493-495.
27. Eichholtz-Wirth, H and Hietel, B. (1990) Heat sensitization to cisplatin in two cell lines with different drug sensitivities International Journal of Hyperthermia, 6, pp. 47-55.
28. Mansouri, A and Henle, KJ and Benson, AM and Moss, AJ and Nagle, WA. (1989) Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia Cancer Research, 49, pp. 2674-2678.
29. Howell, SB and Kirmani, S and McClay, EF and Kim, S and Braly, P and Plaxe, S. (1991) Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma Seminars in Oncology, 18(1 Suppl 3), pp. 5-10.
30. Hebert, ME and Blivin, JL and Kessler, J and Soper, JT and Oleson, JR. (1995) Anaphylactoid reactions with intraperitoneal cisplatin Annals of Pharmacotherapy, 29, pp. 260-263.
31. Piver, M and Fanning, J and Craig, K.(1993) Ovarian cancer. In Gynecologic oncology, 2nd ed. (pp. 250-292). New York: McGraw-Hill.
32. Alberts, DS and Markman, M and Armstrong, D and Rothenberg, ML and Muggia, F and Howell, SB. (2002) Intraperitoneal therapy for stage III ovarian cancer: A therapyAwhose time has come: a theraphy whose time has come! Journal of Clinical Oncology, 20, pp. 3944-3946.
33. Vergote, I and Piccart, M and Scafone, G and et al. Randomized phase III EORTC-GCG study comparing intraperitoneal (ip) cisplatin (p) versus observation in ovarian cancer (O.C.) patients (pts) with a pathologically complete remission (pCR) after first-line chemotherapy. Proceedings from the 2004 Annual Meeting of the Society of Gynecologic Oncologists. In [pp.].
34. Walker, JL and Armstrong, DK and Huang, HQ and Fowler, J and Webster, K and Burger, RA and Clarke-Pearson, D. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study Gynecologic Oncology, 100, pp. 27-32.